Many of you have been following the Abbott Laboratories
story regarding its Kaletra AIDS drug and the conflict with the government of Thailand over patent protection and drug pricing. Some of you may regard this as a relatively isolated tiff between a single drug company and another developing country. Others consider this to be a ......Full article >>>
iland, remarking that Abbott has spent over $300 million last year alone in humanitarian relief worldwide. Activists as well as shareholders supportive of the Abbott decision spar (fortunately peaceably).
Without taking sides, this sounds to me like a lose-lose situation out of a Shakespearean "tragicomedy," layered by miscommunication and blinkered outlooks. Both sides have valid points,......Full article >>>
ieved a short-term victory on Aluvia pricing, but it lost out on significant other life-saving medicines for their population. That being said, AIDS is a monumental problem
in Thailand. The prevalence in that population is estimated at over one percent, which consequently makes AIDS one of the leading causes of death in that country. To a large exten......Full article >>>
s are exporting medicines to developing countries. That reason is called comparative advantage. The U.S. has a comparative advantage relative to other nations in quite a few industries. Aircraft is one of them, military technology is another, financial services also ranks high on the list and, of course, pharmaceuticals and medical technology are significant sources of comparative advantage.
......Full article >>>
t opportunity at medical diplomacy and a failed chance at improving the perception of the U.S. among other nations.
The efforts of U.S. companies to export healthcare technology and medical expertise to other nations becomes not just a business matter but something that should be part of our foreign policy and all the support and encouragement that entails.
So how does this broad......Full article >>>
usly speaking about the Civil War and arguing not only for his vision of a united United States but perhaps more importantly pointing out the state of mind required to achieve that vision. In our time, the dogma that innovation justifies high prices is not necessarily invalid, but we need to think anew and act anew.
Previous articles by Ogan Gurel
Source:wistechnology.com By Ogan Gurel 05/01/07Related biology technology :1
. A prognosis for GE and Abbott Diagnostics2
. Wisconsin court halts Abbotts sale of genotyping products3
. Wisconsin court affirms damages in Innogenetics, Abbott patent case4
. Abbott Labs campus in Kenosha could send ripples through local biotech5
. Abbott Executive Jim Tyree Takes IBIO Helm6
. Promega Announces Agreement with Abbott7
. Changes to U.S. patent law must nurture our culture of innovation8
. Visions: Benson touts embedded innovation9
. UW System must remove barriers to innovation10
. In western Wisconsin, the innovation economy is growing11
. Scott Converse, UW-Madison School of Business, on the innovation mind-set